FINHUB Insights

VTRS · Q1 FY26 · Mar 31, 2026

Viatris Q1 FY26: where the revenue came from and where it went

Viatris Q1 FY26: revenue $3.5B (+8% year over year). Net profit $0B. Largest cohort Brands $2.3B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
May 7, 2026 10-Q
Sankey diagram of Viatris's income statement for Q1 FY26: revenue of $3.5 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.5B +8% year over year
Gross profit$1.2B 33% margin
Operating profit$-0.1B -2% margin
Net profit$0B 0% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 3.5 100% +8%
Brands 2.3 66% +10%
Lipitor 0.5 14% +19%
Other 0.1 3%
Lyrica 0.1 3% +7%
Creon 0.1 3% +18%
Viagra 0.1 3%
Zoloft 0.1 3% +21%
Celebrex 0.1 3%
Cost of revenue−2.469%
Gross profit1.233% margin−3pp
Research & development−0.27%+0pp
SG&A−0.926%−3pp
Other−0.12%+0pp
Operating profit-0.1-2% margin+86pp
Interest & other costs−0.3
Net profit00%+0pp
Filing on EDGAR More quarters of VTRS

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters